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Key Points
• The administration
of third-party FMT
capsules early after
allogeneic HCT is fea-
sible and appears safe.
• FMT is associated with
early expansion of
microbiome diversity in
transplant recipients.
We hypothesized that third-party fecal microbiota transplantation (FMT) may restore intestinal
microbiome diversity after allogeneic hematopoietic cell transplantation (allo-HCT). In this open-
label single-group pilot study, 18 subjects were enrolled before allo-HCT and planned to receive
third-partyFMTcapsules. FMTcapsuleswere administeredno later than4weeksafterneutrophil
engraftment, and antibiotics were not allowedwithin 48 hours before FMT. Five patients did not
receive FMT because of the development of early acute gastrointestinal (GI) graft-versus-host
disease (GVHD) before FMT (n5 3), persistent HCT-associated GI toxicity (n 5 1), or patient
decision (n5 1). Thirteen patients received FMT at a median of 27 days (range, 19-45 days) after
HCT. Participants were able to swallow and tolerate all FMT capsules, meeting the primary study
endpoint of feasibility. FMTwas toleratedwell,with 1 treatment-related signiﬁcant adverse event
(abdominal pain). Two patients subsequently developed acute GI GVHD, with 1 patient also
having concurrent bacteremia.No additional cases of bacteremia occurred.Median follow-up for
survivors is 15 months (range, 13-20 months). The Kaplan-Meier estimates for 12-month overall
survival and progression-free survival after FMT were 85% (95% conﬁdence interval, 51%-96%)
and 85% (95% conﬁdence interval, 51%-96%), respectively. There was 1 nonrelapse death
resulting from acute GI GVHD (12-month nonrelapse mortality, 8%; 95% conﬁdence interval,
0%-30%). Analysis of stool composition and urine 3-indoxyl sulfate concentration indicated
improvement in intestinal microbiome diversity after FMT that was associated with expansion
of stool-donor taxa. These results indicate that empiric third-party FMTafter allo-HCT appears to
be feasible, safe, and associatedwith expansion of recipientmicrobiome diversity. This trial was
registered at www.clinicaltrials.gov as #NCT02733744.
Introduction
The role of the intestinal microbiota and its potential influence on clinical outcomes for patients
undergoing allogeneic hematopoietic cell transplantation (allo-HCT) has been investigated in recent
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years.1-3 Multiple factors contribute to significantly reduced micro-
biota diversity in patients undergoing allo-HCT, including previous
and peri-HCT use of antibiotics, administration of chemotherapy
and/or radiation, and altered nutritional patterns. Analyses of fecal
specimens taken from recipients of allo-HCT around the time of
engraftment have shown that reduced intestinal microbiome
diversity is associated with significantly worse survival outcomes,
and that changes in microbiota composition may influence
important clinical outcomes such as acute graft-versus-host
disease (GVHD) and disease relapse.4-6 Although these associa-
tions between microbiome diversity and clinically important
outcomes after allo-HCT do not demonstrate causality, they provide
data to support clinical evaluation as to whether these relationships
can be modified to influence outcomes for patients.
We hypothesize that approaches to restore a patient’s microbiome
diversity after HCT may improve outcomes after HCT. Although such
approaches to restoring microbiome diversity are still investigational,
fecal microbiota transplantation (FMT) from a healthy individual
carries promise, as initial studies have shown this approach to be
a remarkably effective therapy for recurrent Clostridium difficile
infection, for which loss of microbiome diversity is an important
predisposing factor.7 Early approaches to FMT for C difficile colitis
administered liquid fecal inocula by invasive methods such as
nasogastric intubation or endoscopy.8,9 A novel approach to FMT
administration is through third-party frozen, encapsulated inoculum,
which can be delivered by the oral route.10,11 In this pilot study, we
investigated whether empiric third-party frozen FMT capsules would
be safe and feasible after allo-HCT, and would be able to restore
recipient microbiome diversity.
Methods
Patients
This study was approved by the Institutional Review Board at the
Dana-Farber Harvard Cancer Center and conducted under IND
16857 (Holder: E. Hohmann). The study was conducted at the
Massachusetts General Hospital Cancer Center. Written in-
formed consent was obtained from all subjects. This trial was
registered at ClinicalTrials.gov (NCT02733744). Patients were
between the ages of 18 and 75 years and undergoing a first allo-
HCT. Eligible conditioning regimens were myeloablative or the
combination of fludarabine with melphalan (100-140 mg/m2). Any
GVHD prophylaxis regimen was allowed at the discretion of the
treating physician. Donors were 8/8 HLA-matched related or
unrelated, or haploidentical. Stem cell sources were peripheral
blood precursor cells or bone marrow grafts. Patients with a
history of inflammatory bowel disease, delayed gastric emptying
syndrome, or active gastrointestinal infection were excluded from
the trial. In addition, patients who developed acute GI GVHD after
HCT and before FMT administration were withdrawn from the trial
out of concerns for safety. The decision to use prophylactic
antibiotics during the peri-HCT period was at the discretion of the
treating physician.
FMT capsule preparation
FMT donors were healthy, nonpregnant adults between the ages of 18
and 50 years. Donors had a normal body mass index (19-25 kg/m2)
and did not take any medications on a regular basis; oral contracep-
tives were allowed. Volunteers were excluded for any significant
medical history, employment as a healthcare worker, travel outside
the United States, or use of antibiotics in the preceding 6 months.
Candidates passed the American Association of Blood Banks
donor questionnaire, physical examination, and general laboratory
screening tests. Screening tests performed on donor blood and
stool are listed in supplemental Table 1. All tests were within normal
ranges or negative for all infectious screening tests (including
cytomegalovirus), and the specified virologic screens were re-
peated after donation before samples were used. A fecal
suspension was prepared in normal saline without preservatives,
using a commercial blender in ambient air, and sequentially sieved
to remove particulates. The final slurry was concentrated by
centrifugation and resuspended in saline at one-tenth the volume of
the initial sample, with 20% glycerol added as a bacterial cryoprotec-
tant. The final fecal microbial solution was pipetted into size 0 capsules
(650 mL) that were closed and then secondarily sealed in size 00
capsules (DR Capsules; Capsugel, Greenwood, SC). Capsules were
stored frozen at 280°C (2112°F). Capsules were transported to
the clinic or bedside on dry ice. Thirty capsules contained the
microbial content of a median 38.6 g of feces (range, 24-56.7 g). In
this study, FMT capsules were generated from 2 individual FMT
donors, with patients receiving capsules from a single donor.
FMT capsule administration and specimen collection
The study schema is shown in Figure 1. FMT was administered no
later than 4 weeks after neutrophil engraftment, and antibiotics were
not allowed in the 48 hours before FMT. Patients were given a
single standard dose of oral FMT, based on our published work for
treatment of recurrent C difficile colitis, which is 15 capsules per
day for 2 consecutive days, for a total of 30 capsules.9-11 The
capsules were administered each day at an outpatient clinic visit.
Participants fasted for 4 hours before and 1 hour after capsule
intake. Patients had up to 4 hours to swallow the capsules.
Capsules could not be crushed, chewed, or dissolved. Stool and
urine samples were collected before HCT, 1 week post-HCT, and at
5 points after the FMT administration (1 week, 1 month, 2 months,
6 months, and 12 months). Urine specimens were aliquoted in
cryogenic vials and stored at 280°C until time of sample analysis.
For bacterial analysis of stool specimens, 95% ethanol solution was
added to stool samples in a 1:1 wt/vol ratio and mixed and stored at
280°C until sequencing analysis.
Analysis of urinary 3-IS
Analysis of the tryptophan metabolite 3-indoxyl sulfate (3-IS) was
performed by reverse-phase liquid chromatography-electrospray
ionization-tandem mass spectrometry in negative ion multiple
reaction monitoring mode, as previously described.12,13 Obtained
concentration values were corrected to urinary creatinine.
Analysis of stool specimens
Genomic 16S ribosomal sequencing was performed on stool
specimens, as previously described.5,14 Briefly, genomic bacterial
DNA was extracted from fecal specimens, and the 16S ribosomal-
RNA V4-V5 variable region was amplified and sequenced on the
Illumina MiSeq platform.4,5 VSEARCH was used for analyzing
nucleotide sequences.15 Paired-end reads were merged, de-
replicated, and sorted by length and size. For analyses of bacterial
origin, sequences were error-corrected and chimera-filtered, using
the UNOISE algorithm (http://www.biorxiv.org/content/early/2016/
10/15/081257) to generate a preliminary list of operational
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taxonomic units (OTUs). For analyses of Clostridiales abundance
and diversity as measured by inverse Simpson diversity index, an
internally developed closed-reference OTU reference was used to
classify sequences, and taxonomy was assigned in QIIME,16 using
the Mothur method17 and the August 2013 release of the
Greengenes reference taxonomy.18 An OTU table was generated
using VSEARCH, and UniFrac19 distances between samples were
determined with QIIME. For assessment of the inverse Simpson
diversity score, sample sequences were first rarefied at a number
below the sample, with the least number of sequences (n 5 1152)
using QIIME. All sequencing files and our internal OTU reference
will be made available in the European Nucleotide Archive.
Data collection and management
Study data were collected and managed using REDCap
electronic data capture tools hosted by Partners HealthCare
Research Computing, Enterprise Research Infrastructure & Ser-
vices group. REDCap is a secure, web-based application
designed to support data capture for research studies.20
Subset analysis and comparison cohort with patients
not receiving FMT
An exploratory subset analysis was performed to identify a group of
patients that may benefit most from FMT after HCT based on
exposure to broad-spectrum antibiotics. As this was a pilot study
primarily aimed at establishing feasibility and safety of FMT in
allogeneic HCT recipients, no control group was incorporated into
the study design. In an exploratory analysis of the association of FMT
with changes in microbiome diversity in this subgroup compared with
what occurs in the absence of FMT, a comparison cohort of patients
who did not receive FMTwas retrospectively assembled. The patients
in this comparison cohort were treated at Memorial Sloan Kettering
Cancer Center or Duke University Medical Center and had stool
specimens collected after allo-HCT as part of observational studies.
The selection of patients for this cohort was based on broad-
spectrum antibiotic exposure during HCT hospitalization, as well as
availability of stool samples for sequencing analysis. Stool specimens
from patients in the comparison cohort were analyzed according to
the same methods listed here.
Statistical methods
This was an open-label, single-arm, pilot study evaluating FMT
administered after allogeneic HCT to 13 adult patients. The primary
endpoint of the study was feasibility, which was evaluated by the
proportion of patients who were eligible for FMT administration and
who were able to swallow 15 or more capsules (of 30). FMT was
considered feasible if this proportion was 80% or higher and not
feasible if it was 50% or lower. Secondary endpoints included
cumulative incidence of bloodstream infections, C difficile colitis,
and acute GVHD, as well as estimates for nonrelapse mortality,
progression-free survival, and overall survival (OS). Progression-free
survival and OS were estimated using the Kaplan-Meier method.
Progression-free survival was calculated from the date of FMT
administration to disease progression or death from any cause.
Patients who were alive without relapse or progression were censored
at the time of last clinical evaluation. OS was calculated from the date
of FMT administration to death or censored at last clinical evaluation.
The cumulative incidence of nonrelapse mortality was estimated with
relapse as a competing risk. Comparisons of microbiome parameters
(urinary 3-IS,Clostridiales abundance, inverse Simpson diversity index,
UniFrac distance) were performed using the Mann-Whitney U test.
Results
Patient characteristics
Eighteen patients were enrolled on the study before admission for HCT.
Five patients did not receive FMT because of the development of early
acute GI GVHD before FMT (n 5 3), patient withdrawal of consent
before HCT (n 5 1), and prolonged chemotherapy-associated
gastrointestinal toxicity (n5 1; Figure 2). Baseline patient and transplant
characteristics of the 13 patients who received FMT are shown in
Table 1. The median age was 63 years (range, 26-71 years). Of those
given FMT, 7 were female and 6 were male. The most common
underlying diagnoses were acute myeloid leukemia (n 5 4), myelodys-
plastic syndrome (n5 3), and non-Hodgkin lymphoma (n5 3). Donors
included matched unrelated (n 5 9), matched related (n 5 2), and
haploidentical (n 5 2). Twelve patients received peripheral blood
precursor cells, and 1 patient received a bone marrow graft. Ten
patients received reduced-toxicity conditioning with fludarabine and
melphalan, and 3 received conventional myeloablative regimens. GVHD
prophylaxis regimens included tacrolimus/sirolimus (n5 9), tacrolimus/
methotrexate (n 5 2), and posttransplant cyclophosphamide with
tacrolimus/mycophenolate mofetil for the 2 haploidentical transplants.
Antibiotic exposures beginning at the time of HCT hospitalization
through day 160 are summarized in supplemental Table 2.
Safety and toxicity
Fourteen patients were deemed eligible for evaluation of the
feasibility endpoint: the 13 patients who received FMT and the
single patient with prolonged chemotherapy-related gastrointestinal
toxicity. All thirteen patients who received FMT capsules were able
to swallow all 30 capsules (15 capsules/day for 2 consecutive
days). Patients swallowed the daily allotment of capsules within
30 minutes. Thus, the primary endpoint of the study was met, as
13 (93%) of 14 patients eligible to receive FMT were able to take 15
or more of 30 capsules. There was only 1 serious treatment-related
adverse event (grade 3 abdominal pain), and this resolved within
Stem cell
infusion
Neutrophil
engraftment
Standard dose
FMT
4 weeks after neutrophil engraftment
and 48 hours off antibiotics
Conditioning
Admission to
hospital
Figure 1. Study schema.
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24 hours of capsule administration. There was no treatment-related
nausea, vomiting, or diarrhea reported.
Clinical outcomes
Clinical outcomes are summarized in Table 2. FMT capsules were
administered at a median of 27 days (range, 19-45 days) after HCT.
Median follow-up for survivors is 15 months (range, 13-20 months).
Two patients developed grade 3-4 acute GI GVHD subsequent to
FMT. One case of severe GI GVHD occurred 20 days after FMT in
a patient who had to prematurely discontinue tacrolimus after
developing posterior reversible encephalopathy syndrome. The
patient also developed Klebsiella pneumoniae bacteremia and
sepsis, with subsequent multiorgan failure. In the second, skin
manifestations of GVHD were noted 7 days after FMT, with the
onset of GI involvement weeks later. There were no additional cases
of bacteremia after FMT. There was 1 case of C difficile colitis
observed after FMT. Six patients have developed moderate-severe
chronic GVHD. The Kaplan-Meier estimates for 12-month OS
and progression-free survival after FMT were 85% (95% confi-
dence interval, 51%-96%) and 85% (95% confidence interval,
51%-96%), respectively. There was 1 nonrelapse death, which was
a result of acute GI GVHD (12-month nonrelapse mortality, 8%;
95% confidence interval, 0%-30%).
Correlative analysis of serial stool and
urine specimens
Low urinary concentrations of 3-IS after HCT are indicative of
significant and clinically relevant intestinal microbiota disruption.13
A significant decrease in the median urinary 3-IS level was noted
when comparing the pre-HCT with the post-HCT/pre-FMT spec-
imen (34.59 umol/mmol creatinine vs 4.36; P # .0001; Figure 3).
Furthermore, there were significant increases in 3-IS in the urinary
specimens collected 1 week (4.36 vs 36.57; P 5 .0006) and
1 month (4.36 vs 40.89; P 5 .001) after FMT when compared with
the post-HCT/pre-FMT specimen.
There was no statistically significant change in the intestinal
microbiome a-diversity between the pre-HCT specimens and the
post-HCT/pre-FMT or post-FMT specimens, as measured by the
inverse Simpson index (Figure 4A). A significant decrease in
Clostridiales abundance was observed when comparing the pre-
HCT with the post-HCT/pre-FMT stool specimen, which corrected
after FMT (Figure 4B). UniFrac distance analysis showed a more
similar microbiome in patients when compared with their FMT donor
after the administration of FMT than before FMT (Figure 4C). To
assess engraftment of the FMT product, OTU origins were
classified as being initially identified in the FMT donor sample only,
in the patient pre-FMT samples only, both, or neither. Expansion of
FMT donor-only OTUs was clearly observed in recipients after
administration of FMT (Figure 4D).
Subset analysis and comparison cohort with patients
not receiving FMT
According to the known association between antibiotic exposure
and reduced microbiome diversity,21 we identified 8 patients who
both received broad-spectrum antibiotics (not including ciproflox-
acin prophylaxis) during HCT hospitalization before FMT and, thus,
likely experienced an initial microbiota injury, and did not receive
broad-spectrum antibiotics after FMT, which we hypothesized
would increase the likelihood of durable engraftment of the FMT.
This subset of patients experienced more significant increases in
microbiome diversity, as measured by urinary 3-IS, inverse Simpson
index, Clostridiales abundance, and shorter UniFrac distance from
Number of patients enrolled on study prior to HCT: 18
Patient withdrew consent prior to HCT (n=1)
Patients developing acute GI GVHD prior to FMT (n=3)
Number of patients eligible to receive FMT: 14
Patient with persistent HCT-related GI toxicity (n=1)
Number of patients receiving FMT: 13
Major eligibility criteria:
Adult patients (18 year of age) receiving allogeneic transplant
8/8 HLA-matched related or unrelated donor or haploidentical donor
Myeloablative or fludarabine/melphalan conditioning regimen
Any GVHD prophylaxis
No history of IBD, delayed gastric emptying syndrome, active GI
infection
No acute GI GVHD prior to FMT
Figure 2. Study flow diagram. IBD, inflammatory bowel disease.
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the FMT donor (Figure 5). For a comparison cohort, we identified
32 patients from 2 other institutions who received broad-spectrum
antibiotic exposure during their HCT hospitalization and had
available 16S-sequenced stool samples, but who did not receive
an FMT. As the median time of FMT administration was 27 days
after HCT (range, 19-45 days), we chose stool samples collected
at points days 25-40 and days 50-70 after HCT for the control
cohort to compare with the 1-week and 1-month post-FMT
samples. In this unplanned post hoc analysis, patients who
received FMT on this study had significantly improved intestinal
microbiome diversity, as measured by the inverse Simpson index
(Figure 6).
Discussion
This pilot study is the first to explore the empiric administration of
frozen third-party oral FMT capsules to patients early after allo-HCT
to reconstitute microbiome diversity. We found that third-party FMT
was safe and feasible when given in the period immediately after
neutrophil engraftment. The primary endpoint of the study, feasibility
of oral FMT early after allo-HCT, was met. We also found the
approach to be safe, as patients experienced minimal toxicity and a
low incidence of infectious complications. We did not observe
transmission of infectious organisms from FMT capsules. There was
a single case of bacteremia after administration of FMT, which
occurred in the setting of active GI GVHD. We are encouraged by
the safety and feasibility demonstrated, as there are multiple
advantages to oral third-party FMT capsules, including noninvasive
administration, centralized screening of donors and preparation of
an FMT product, and the ability to treat many patients from a few
healthy donors. This formulation and route of administration are
perhaps more readily scaled up to multicenter studies than a liquid
FMT preparation collected freshly and delivered via nasogastric
intubation, enema, or endoscopically.
Our results also represent the first outside validation of urinary 3-IS,
a tryptophan-derived metabolite produced by commensal bacteria,
as a biomarker for microbiome diversity in allo-HCT patients. The
patients in this study exhibited an expected decrease in microbial
diversity while undergoing HCT, as predicted by the biomarker
urinary 3-IS concentration, although this change was not statisti-
cally significant when assessed directly by 16S sequencing and the
inverse Simpson index. The reason for this may be that urinary 3-IS
concentration and stool 16S-based diversity measurements each
detect different, and perhaps overlapping, patterns of microbiota
injury. The administration of FMT in this study was associated with
maintenance or recovery of intestinal microbiome diversity, as
indicated by urinary 3-IS levels and 16S ribosomal sequencing of
stool specimens, which could be observed as early as 1 week after
FMT. Furthermore, there was clear expansion of donor-specific
OTUs, suggesting that the recovery of microbiome diversity was
directly attributable to the FMT. Previous studies have identified
Clostridiales as a commensal anaerobe with an important role in
intestinal homeostasis, and its loss during allo-HCT has been
associated with increased transplant-related mortality.4,22 The
increase in Clostridiales abundance after FMT is consistent with
0
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Figure 3. Longitudinal changes in urinary 3-IS levels before allo-HCT and
after FMT administration in the early posttransplant period.
Table 2. Clinical outcomes
Outcome Value
Patients receiving FMT, n 13
Median time from allo-HCT to FMT (range), d 27 (19-45)
Median follow-up (range), mo 15 (13-20)
C difficile colitis, n 1
Bacteremia, n 1
Grade 3-4 acute GVHD, n 2
Deaths, n 2
Table 1. Baseline characteristics
Characteristic Value
Median age (range), y 63 (26-71)
Sex, female/male, n 7/6
Diagnosis, n
Acute myeloid leukemia 4
Myelodysplastic syndrome 3
Non-Hodgkin lymphoma 3
Myeloproliferative disorder 1
Chronic lymphocytic leukemia 1
Myelofibrosis 1
Graft source, n
Peripheral blood stem cells 12
Bone marrow 1
Donor, n
Matched unrelated 9
Matched related 2
Haploidentical 2
Conditioning, n
Reduced intensity 10
Myeloablative 3
GVHD prophylaxis, n
Tacrolimus/sirolimus 9
Tacrolimus/methotrexate 2
Posttransplant cyclophosphamide plus tacrolimus/
mycophenolate mofetil
2
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the other measures of microbiome health. We also retrospectively
identified a subset of patients in this study who received broad-
spectrum antibiotics during HCT hospitalization who appear to have
attained the largest gains in terms of microbiome diversity after
FMT. When compared with a post hoc cohort of allo-HCT patients
from other institutions with similar antibiotic exposures but who did
receive FMT, patients who received FMT had significantly improved
intestinal microbiome diversity. Clearly, these comparisons must be
interpreted with caution, given the differences between institutional
clinical practices and the limitations of retrospective analyses.
Nevertheless, taken together with the expansion of donor-specific
taxa we observed, these results are consistent with the notion that
the improvements in microbiome diversity in this study can be, in
part, attributed to the FMT.
The loss of intestinal microbial diversity has recently been associated
with adverse outcomes in recipients after allo-HCT. Reduced diversity
of the intestinal microbiome within the first 7 days after neutrophil
engraftment, as measured by 16S rRNA sequencing and defined by
the inverse Simpson index, has been correlated with significantly worse
survival outcomes (OS at 3 years was 36%, 60%, and 67% for low-,
intermediate-, and high-diversity groups, respectively (P 5 .019).4
Similarly, low levels of urinary 3-IS in the first 10 days after allo-
HCT have been associated with higher transplant-related mortality
(P 5 .017) and worse OS (P 5 .05), with the majority of TRM being
related to acute GI GVHD (86.4%; P , .001).13 Subsequent studies
have explored associations between the intestinal microbiome with
acuteGVHD and disease relapse. One analysis showed that increased
bacterial diversity after allo-HCT was associated with reduced acute
GVHD-related mortality, and that increased amounts of bacteria
specifically belonging to the genus Blautia were associated with
reduced acute GVHD mortality.5 In a second study, acute GVHD was
associated with lower a diversity of stool microbiota, with the presence
of oralActinobacteria and oral Firmicutes in stool at neutrophil recovery
after allo-HCT being positively correlated with subsequent acute
GVHD.23 Finally, a link between disease relapse after allo-HCT and the
changes in the amount of specific bacteria in the intestinal flora has
been demonstrated, notably with higher Eubacterium limosum
abundance being associated with a decreased risk for relapse.6
It remains unknown whether interventions designed to modify the
microbiome can affect clinical HCT outcomes, but numerous initial
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Figure 4. Evaluation of the microbiome prior to and following administration of FMT. Longitudinal changes in (A) inverse Simpson index, (B) Clostridiales abundance, and (C)
UniFrac distance before allo-HCT and after FMT administration in the early posttransplant period, as determined from 16S rRNA sequencing of stool specimens. (D) Longitudinal changes in
the origin of operational taxonomic units. Four selected patients shown.
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investigations are underway. Early administration of broad-spectrum
antibiotic therapy is associated with significantly altered microbiota
(reflected by suppression of urinary 3-IS levels), higher TRM, and
worse OS when compared with patients with late or no antibiotic
exposure.13,21 It has been hypothesized that commensal anaerobic
organisms, such as Clostridiales, help maintain and restore micro-
biota diversity, and that the use of anaerobe-sparing antibiotics may
benefit patients.21,24 Indeed, multiple prospective clinical trials are
evaluating the effect of choice of antibiotic prophylaxis or empiric
therapy for neutropenic fever on the intestinal microbiome during
allo-HCT (NCT02641236, NCT03078010). In addition, the use of
certain prebiotics and probiotics are being explored as possible
approaches to prevent microbiota dysbiosis.25 Murine models have
identified microbiome-derived metabolites, which may mitigate GI
toxicity and GVHD, although clinical investigations in humans have
not yet been reported.26,27 An ongoing pilot study is investigating
the administration of fructooligosaccharides, a prebiotic with known
ability to alter butyrate-producing bacteria,28 to patients undergo-
ing allo-HCT (NCT02805075). In addition, there is a planned
randomized clinical trial to study the role of Lactobacillus in
preventing acute GI GVHD in pediatric recipients of HCT
(NCT03057054). Exposure to the hospital environment may also
have an effect on the intestinal microbiome, and it has been
recently shown that patients who received care after transplant at
home had similar outcomes to matched hospital controls, with a
noted lower incidence of grade 2-4 acute GVHD.29 An ongoing
study will evaluate changes in the intestinal microbiota for patients
who receive HCT at home, as compared with those treated in the
clinic or hospital (NCT01725022).
Previous investigations of FMT in HCT recipients have focused
mainly on the treatment of antibiotic-resistant bacteria and
C difficile infection.30-33 A prospective single-center study in
patients with blood disorders, which included HCT recipients,
suggested that FMT can eradicate antibiotic-resistant bacteria from
the GI tract of recipients.34 A randomized trial of empiric autologous
FMT to prevent C difficile infection in allo-HCT recipients is now
ongoing (NCT02269150). Interestingly, 2 recent preliminary
reports have suggested a possible role for FMT as treatment of
steroid-refractory acute GI GVHD.35,36 These interventional stud-
ies, as well as the associations of low intestinal microbial diversity
with the risk for infectious complications, acute GVHD, and TRM,
suggest that microbiome restoration early after allo-HCT may be of
benefit. Here, we show that frozen third-party FMT capsules allow
for an easily accessible, noninvasive approach that is well tolerated
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Figure 5. Microbiome assessment under conditions that highlight the potential benefit of FMT as part of an exploratory analysis in a subset of 8 patients.
Eligibility criteria for inclusion in this subset analysis received microbiome-disrupting antibiotics (ceftazidime, cefepime, piperacillin-tazobactam, meropenem, oral vancomycin, or
metronidazole) before FMT, and did not receive microbiome-disrupting antibiotics in the 60 days after FMT.
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in the early post-HCT period and can potentially hasten the recovery
of microbiome diversity.
Limitations of this study include primarily the small sample size.
A pilot safety and feasibility study was necessary, given that
participants were receiving donor live bacteria in the immediate
post-HCT period. This design inherently limits our ability to draw any
conclusions about whether microbial manipulation by FMT directly
influenced patient outcomes, as that requires a larger study with
incorporation of a proper control group. In addition, given safety
concerns about the risk for FMT-related bacteremia, we excluded
patients with acute GI GVHD, as active inflammation compromises
the integrity of the intestinal barrier. Given our data associating FMT
with restoration of microbial diversity, and preliminary reports of
the therapeutic effect of FMT in patients with steroid-resistant
aGVHD,35,36 additional studies should be designed to investigate
the effect of FMT on clinical outcomes after allo-HCT, including
acute GVHD and infectious complications.
Further prospective evaluations into the use of FMT in patients
undergoing allogeneic HCT are needed to better understand its
effects on the recipient microbiome and to better characterize
its influence on clinical outcomes. Given the limited size of
current clinical studies, microbiome diversity-associated correlative
endpoints seem most appropriate. However, a larger prospective
trial with a clinical primary endpoint will eventually be required to
ultimately determine whether microbiome diversity manipulation can
truly have an effect on patient outcomes after allo-HCT.
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